Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.266490 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Romain-David Seban. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
REPLY: I extend my gratitude to Altena et al. for their insightful response to our letter to the editor ([1][1]) regarding human epidermal growth factor receptor 2 (HER2)–targeted PET imaging in breast cancer patients. It is with great enthusiasm that I acknowledge the pivotal role their work
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Seban, R. D. (2023). Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266490
Vancouver
Seban RD. Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.266490
BibTeX
@article{Seban2023,
author = {Seban, Romain-David},
title = {Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.266490}
}
EUVIMED